Stephen Johnson

Array ( [id] => 19127234 [patent_doc_number] => 20240132587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN 18.2 [patent_app_type] => utility [patent_app_number] => 18/481725 [patent_app_country] => US [patent_app_date] => 2023-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43884 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127234 [patent_doc_number] => 20240132587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN 18.2 [patent_app_type] => utility [patent_app_number] => 18/481725 [patent_app_country] => US [patent_app_date] => 2023-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43884 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19390690 [patent_doc_number] => 20240280560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => DETECTION OF ACUTE MYELOID LEUKAEMIA [patent_app_type] => utility [patent_app_number] => 18/451671 [patent_app_country] => US [patent_app_date] => 2023-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18451671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860317 [patent_doc_number] => 20230414751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => PHARMACEUTICAL COMPOSITION CONTAINING EXOSOME AND PREPARATION METHOD THEREOF [patent_app_type] => utility [patent_app_number] => 18/342913 [patent_app_country] => US [patent_app_date] => 2023-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4657 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18342913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034176 [patent_doc_number] => 20240083991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => ANTI-BMP9 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/326335 [patent_app_country] => US [patent_app_date] => 2023-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50137 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18326335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817779 [patent_doc_number] => 20230392119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => COMPOSITIONS AND METHODS FOR PREPARING ENGINEERED LYMPHOCYTES FOR CELL THERAPY [patent_app_type] => utility [patent_app_number] => 18/324012 [patent_app_country] => US [patent_app_date] => 2023-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31604 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18324012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754059 [patent_doc_number] => 20230357431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => IMPROVED ANTIGEN BINDING RECEPTORS [patent_app_type] => utility [patent_app_number] => 18/308290 [patent_app_country] => US [patent_app_date] => 2023-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48663 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18308290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18784833 [patent_doc_number] => 20230372486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => CHIMERIC RECEPTORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/300981 [patent_app_country] => US [patent_app_date] => 2023-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47495 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18300981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769381 [patent_doc_number] => 20230364142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => COMPOSITION FOR ANTIVIRUS COMPRISING NATURAL KILLER CELL [patent_app_type] => utility [patent_app_number] => 18/299204 [patent_app_country] => US [patent_app_date] => 2023-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18299204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097769 [patent_doc_number] => 20240116997 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => ACTIVATABLE IL-18 POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 18/113399 [patent_app_country] => US [patent_app_date] => 2023-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31491 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18113399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18816021 [patent_doc_number] => 20230390360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => METHODS OF USING INTERLEUKIN-2 AGENTS [patent_app_type] => utility [patent_app_number] => 18/167529 [patent_app_country] => US [patent_app_date] => 2023-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74551 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18167529 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511422 [patent_doc_number] => 20230227572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => ANTI-PVRIG PROTEIN ANTIBODY OR ANTIBODY FRAGMENT AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/160886 [patent_app_country] => US [patent_app_date] => 2023-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16051 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18160886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18628287 [patent_doc_number] => 20230287145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => PROTEASE-ACTIVATED T CELL BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/066529 [patent_app_country] => US [patent_app_date] => 2022-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50942 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18066529 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675156 [patent_doc_number] => 20230312743 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => ENGINEERED PD-1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/056410 [patent_app_country] => US [patent_app_date] => 2022-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18056410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673125 [patent_doc_number] => 20230310605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => METHODS FOR CULTURING CELLS EXPRESSING ROR1-BINDING PROTEIN [patent_app_type] => utility [patent_app_number] => 18/050411 [patent_app_country] => US [patent_app_date] => 2022-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 90451 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582892 [patent_doc_number] => 20230265149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => ENCAPSULATED CELLS EXPRESSING IL-2 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/047856 [patent_app_country] => US [patent_app_date] => 2022-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20535796 [patent_doc_number] => 12552861 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-17 [patent_title] => Monoclonal antibody [patent_app_type] => utility [patent_app_number] => 17/938543 [patent_app_country] => US [patent_app_date] => 2022-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 10 [patent_no_of_words] => 3052 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18286872 [patent_doc_number] => 20230102344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => MULTIFUNCTIONAL MOLECULES THAT BIND TO CD33 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/855335 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 106433 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17855335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17895420 [patent_doc_number] => 20220305082 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => CHIMERIC ANTIGEN RECEPTOR SPECIFICALLY BINDING TO CD 300C ANTIGEN OR RECEPTOR THEREOF [patent_app_type] => utility [patent_app_number] => 17/826954 [patent_app_country] => US [patent_app_date] => 2022-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20830 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17826954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19281595 [patent_doc_number] => 20240218069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => BI-SPECIFIC ANTIBODIES COMPRISING ANTI-B7H3 BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 18/556596 [patent_app_country] => US [patent_app_date] => 2022-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -90 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556596 [rel_patent_id] =>[rel_patent_doc_number] =>)